Werewolf Therapeutics, Inc. — Investor Relations & Filings
Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | |
| 8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | |
| 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-24 | English | |
| 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-13 | English | |
| SCHEDULE 13G/A Filing | 2026-02-11 | English | |
| 8-K Filing | 2026-02-06 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 33058433 | 10-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | ||
| 33058414 | 8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | ||
| 32898233 | 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-24 | English | ||
| 32898234 | 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-13 | English | ||
| 31705258 | SCHEDULE 13G/A Filing | 2026-02-11 | English | ||
| 31705271 | 8-K Filing | 2026-02-06 | English | ||
| 13198047 | Director's Dealing 2026 | 2026-01-20 | English | ||
| 13198048 | Major Shareholding Notification 2026 | 2026-01-16 | English | ||
| 13198049 | Director's Dealing 2026 | 2026-01-15 | English | ||
| 13198050 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13198051 | Director's Dealing 2026 | 2026-01-07 | English | ||
| 13198052 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198053 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198054 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198055 | Regulatory Filings 2026 | 2026-01-06 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BriaCell Therapeutics Corp.
Developing targeted cellular immunotherapies using whole-ce…
|
BCTX | CA | Manufacturing |
|
BridgeBio Oncology Therapeutics, Inc.
Clinical-stage biopharma developing inhibitors for genetica…
|
BBOT | US | Manufacturing |
|
BridgeBio Pharma, Inc.
Develops transformative medicines for genetic diseases and …
|
BBIO | US | Manufacturing |
|
Brightgene Bio-Medical Technology Co., Ltd.
Research-driven developer of complex APIs, high-end generic…
|
688166 | CN | Manufacturing |
|
BRIGHT MINDS BIOSCIENCES INC.
Develops selective serotonin agonists for neurological and …
|
DRUG | US | Manufacturing |
|
BrightPath Biotherapeutics Co., Ltd.
A clinical-stage biopharma company developing cancer immuno…
|
4594 | JP | Manufacturing |
|
Brii Biosciences Limited
Developing first-in-class therapies targeting infectious an…
|
2137 | KY | Manufacturing |
|
BRISTOL MYERS SQUIBB CO
A global biopharmaceutical company that discovers, develops…
|
BMY | US | Manufacturing |
|
BROOKS LABORATORIES LIMITED
Pharmaceutical manufacturer specializing in CRAMS and diver…
|
BROOKS | IN | Manufacturing |
|
BUKWANG PHARMACEUTICAL IND CO.,LTD
An R&D-focused company developing drugs for CNS disorders a…
|
003000 | KR | Manufacturing |
Werewolf Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34192/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34192 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34192 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34192 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34192}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Werewolf Therapeutics, Inc. (id: 34192)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.